A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut ...

Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

With the FDA's approval, the medicine, chemically known as semaglutide, will become the first GLP-1 treatment option for persons with type 2 diabetes ... that Ozempic (semaglutide) 1.0 mg lowered ...